Please login to the form below

Not currently logged in
Email:
Password:

Rubraca

This page shows the latest Rubraca news and features for those working in and with pharma, biotech and healthcare.

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

Last year, they entered the prostate cancer setting with the approval of Clovis’ Rubraca (rucaparib) and AstraZeneca and Merck/MSD’s Lynparza (olaparib).

Latest news

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...